Charles River Laboratories International Inc (MEX:CRL)
MXN 3917.07 0 (0%) Market Cap: 200.20 Bil Enterprise Value: 250.74 Bil PE Ratio: 24.84 PB Ratio: 2.99 GF Score: 71/100

Charles River Laboratories International Inc at Barclays Global Healthcare Conference Transcript

Mar 11, 2020 / 02:15PM GMT
Jack Meehan
Barclays Bank PLC, Research Division - VP & Senior Research Analyst

Thank you, and good morning. This is Jack Meehan with the Life Science Tools & Diagnostics team here at Barclays. And pleased to be continuing the Barclays virtual Global Healthcare Conference now with Charles River Chairman and CEO, Jim Foster; as well as Head of Investor Relations, Todd Spencer. I appreciate you guys joining us in the new format. And Jim, just like to turn it over to you for some introductory comments.

James C. Foster
Charles River Laboratories International, Inc. - Chairman, CEO & President

Sure. Thanks. Thanks, Jack. We reported a very strong '19. Sales up 8.5%. Operating margins 19%, up 20 bps. EPS $6.73, up 16%. We were really, really pleased with those results. The guidance for '20 is 7.75% to 8.75% revenue growth and EPS at $7.45 to $7.60.

The RMS segment was up 5 -- a little over 5%, driven principally by China and strength in our GEMS business and IS business. We opened a new facility in South San Francisco, which is an incubated

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot